Schrödinger (SDGR) Stock Surges 60% but $37 Resistance Could Test the Rally as Mixed Fundamentals Raise Fresh Risks

Schrödinger (SDGR) reported Q3 2026 earnings, highlighting 17% ACV growth and 19% total revenue increase. Key drivers included broader adoption in pharmaceuticals, new product introductions like Bunsen, and growth in biotech and material science sectors. The company raised full-year guidance for ACV and drug discovery revenue. Financials included $44.7M in ACV, $64.5M in total revenue, and a net loss of $38M. Hosted software licensing grew to 45% of software revenue.

Schrödinger (SDGR) reported Q3 2026 results, with ACV growth of 17% (24% excluding contributions) and raised 2026 drug discovery revenue guidance to $75M-$85M. The company expects 2026 ACV to be $222M-$232M, reflecting commercial momentum and progress toward long-term goals, according to CEO Ramy Farid.

Schrodinger Inc (SDGR) reported Q3 2026 earnings with a widened net loss of $38M, despite revenue growth. The company raised guidance, citing strong ACV and customer confidence in its technology. Revenue growth is impacted by a transition to hosted licensing. Bunsen, a new product, is in early access, and material science adoption lags behind pharma/biotech. Drug discovery revenue is milestone-dependent, with intensifying competition in AI-driven molecular discovery.

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Third Quarter 2026 Financial Results Third Quarter ACV of $45 Million, Representing 17% Growth Increases Full-Year 2026 ACV and Drug Discovery Revenue Guidance New York, November 4, 2026 – Schrödinger, Inc. (Nasdaq: SDGR) today announced financial

Schrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.